×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Pfizer | Profits | Earnings | Drugs

Pfizer Beats Forecasts as Oncology Drugs Grow

Tuesday, 29 July 2014 07:56 AM EDT

Pfizer Inc., which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

The largest U.S. drugmaker on Tuesday said it had earned $2.91 billion, or 45 cents per share. That compared with $14.1 billion, or $1.98 per share, a year earlier, when Pfizer received more than $10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis.

Excluding special items, Pfizer earned 58 cents per share. Analysts on average expected 57 cents, according to Thomson Reuters I/B/E/S.

Sales fell 2 percent to $12.77 billion, hurt by declines for generic medicines that Pfizer calls established products, but they exceeded Wall Street expectations of $12.46 billion.

Pfizer stuck to its prior earnings forecast of $2.20 to $2.30 per share for the full year.

Shares of Pfizer were up 1 percent at $30.41 in trading before the market opened.


© 2023 Thomson/Reuters. All rights reserved.


Companies
Pfizer Inc., which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.
Pfizer, Profits, Earnings, Drugs
159
2014-56-29
Tuesday, 29 July 2014 07:56 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved